This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia
by Zacks Equity Research
The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
The Zacks Analyst Blog Highlights UnitedHealth, Elevance Health, Humana and Centene
by Zacks Equity Research
UnitedHealth, Elevance Health, Humana and Centene are included in this Analyst Blog.
Will Biden's Tax Hike Plan Extend Medicare's Life to 2050?
by Kaibalya Pravo Dey
U.S. President Joe Biden's proposal is also likely to enhance Medicare's ability to negotiate prices for drugs.
Select Medical (SEM) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Select Medical (SEM) anticipates 2023 revenues to be within $6.5-$6.7 billion.
Why Is Elevance Health (ELV) Down 3.2% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills
by Zacks Equity Research
JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills are part of the Zacks top Analyst Blog.
Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Elevance Health, Inc. (ELV) and Vertex Pharmaceuticals Incorporated (VRTX).
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pediatrix (MD) Q4 Earnings miss on High Operating Expenses
by Zacks Equity Research
Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.
Centene (CNC) Q4 Earnings Miss on High Costs, '23 Premium View Up
by Zacks Equity Research
Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.
Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up
by Zacks Equity Research
Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.
Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat
by Zacks Equity Research
Humana's (HUM) fourth-quarter results benefit from solid premiums from its individual Medicare Advantage business and the sound performance of the two newly formed segments.
Q4 Earnings Season Scorecard and Analyst Reports for Apple, Meta & Mastercard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, Inc. (META) and Mastercard Incorporated (MA).
HCA Healthcare (HCA) Q4 Earnings Lag on High Costs, Hikes Dividend
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results suffer a blow from added expenses incurred due to Hurricane Ian. Increased patient admissions partly offset the downside.
Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.
Elevance Health (ELV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Elevance Health (ELV) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 0.58% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed
by Zacks Equity Research
Home Depot, Merck, Bank of America, Elevance Health and ResMed are included in this Analyst Blog.
Top Analyst Reports for Home Depot, Merck & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).
Why You Should Hold Elevance Health (ELV) in Your Portfolio
by Zacks Equity Research
Elevance Health (ELV) remains well-poised for growth due to a growing customer base within its Government and IngenioRx businesses coupled with solid cash-generating abilities.